Balancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemab
Top Cited Papers
Open Access
- 10 March 2026
- journal article
- review article
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 63, 101644
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Lecanemab Treatment in a Specialty Memory ClinicJAMA Neurology, 2025
- Characterizing the Journey of Early Alzheimer’s Disease in Patients Initiating Lecanemab Treatment in the United States: A Real-World Evidence StudyNeurology and Therapy, 2025
- Modified titration of donanemab reduces ARIA risk and maintains amyloid reductionAlzheimer's & Dementia, 2025
- Estimation Methods for Estimands Using the Treatment Policy Strategy; a Simulation Study Based on the PIONEER 1 TrialPharmaceutical Statistics, 2025
- Minimal clinically important difference in Alzheimer's disease: Rapid reviewAlzheimer's & Dementia, 2024
- Donanemab in Early Symptomatic Alzheimer DiseaseJAMA, 2023
- Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer DiseaseJAMA Neurology, 2020
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- Functional evaluation distinguishes MCI patients from healthy elderly people — The ADCS/MCI/ADL scaleThe Journal of nutrition, health and aging, 2010
- Amyloid deposition as the central event in the aetiology of Alzheimer's diseaseTrends in Pharmacological Sciences, 1991